Introduction
============

Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder in both children and adults.[@b1-ndt-13-357] The global incidence of ADHD in children (ie, less than 18 years of age) ranges between 5.9% and 7.1%, and in adults, it ranges between 3% and 5%.[@b1-ndt-13-357]--[@b3-ndt-13-357] A considerable proportion of individuals diagnosed with ADHD as children continue to need long-term therapy into adulthood[@b4-ndt-13-357],[@b5-ndt-13-357] and are at risk for continued difficulties with employment, social interactions, and education, and even have increased mortality risk.[@b4-ndt-13-357],[@b6-ndt-13-357],[@b7-ndt-13-357]

Complicating the clinical picture of patients with ADHD is the realization that a majority of these patients are likely to have coexisting psychiatric disorders.[@b8-ndt-13-357]--[@b11-ndt-13-357] A recent study of 14,825 patients in Danish psychiatric inpatient or outpatient clinics who were between the ages of 4 and 17 years and diagnosed with ADHD for the first time between 1995 and 2010 found that 52% had at least 1 comorbid disorder and 26% had 2 or more comorbid disorders.[@b8-ndt-13-357] The incidence of comorbidities in children with ADHD is summarized in [Table 1](#t1-ndt-13-357){ref-type="table"}.

It appears that adults with ADHD may have a higher incidence of comorbid disorders than do children. In a large family study, it was found that 87% of adults with ADHD had at least 1 comorbid psychiatric disorder, and 56% had at least 2 disorders.[@b22-ndt-13-357] In this study, the most common comorbidities were anxiety, depression, mood disorders, and substance use disorder (SUD). Of note, adult ADHD is under-treated;[@b23-ndt-13-357]--[@b25-ndt-13-357] consequently, treatment paradigms for adults, especially in the presence of a comorbid condition, are not as well established as for children, emphasizing the importance of establishing reliable treatment paradigms in this population. The incidence of comorbidities in adults with ADHD is summarized in [Table 2](#t2-ndt-13-357){ref-type="table"}. [Tables 1](#t1-ndt-13-357){ref-type="table"} and [2](#t2-ndt-13-357){ref-type="table"} provide detailed insight into the incidence of each type of comorbidity, and list the comorbidities for which no studies were identified in the literature search.

Although the stimulants, which include various formulations of methylphenidates and amphetamines, provide good efficacy in treating symptoms of ADHD, these drugs are often contraindicated in patients with comorbid disorders, including Tourette's syndrome and bipolar disorder, as well as in patients at risk for substance abuse.[@b30-ndt-13-357]--[@b32-ndt-13-357] Further, some investigators advise caution in prescribing these products to patients with comorbid disorders that are not explicitly contraindicated, such as tic disorders[@b33-ndt-13-357] and anxiety.[@b3-ndt-13-357],[@b34-ndt-13-357] Suicidal ideation is a symptom that may be present in ADHD patients with comorbid psychiatric disorders, especially depression and bipolar disorder. The presence of suicidal ideation in ADHD patients is a contraindication for methylphenidate in the European Union (EU).[@b32-ndt-13-357] The labeling of both the EU and the US has a warning regarding suicidal ideation in child ADHD patients taking atomoxetine.[@b35-ndt-13-357]--[@b38-ndt-13-357]

The selective noradrenergic reuptake inhibitor atomoxetine is approved for the treatment of ADHD in children and adults.[@b6-ndt-13-357] Moreover, it has no abuse potential, and consequently, atomoxetine is considered a first-line therapy for patients at risk for substance abuse disorders.[@b28-ndt-13-357],[@b39-ndt-13-357],[@b40-ndt-13-357] In addition, atomoxetine is often preferred over stimulants for patients with ADHD and comorbid tic disorders or anxiety.[@b28-ndt-13-357],[@b33-ndt-13-357],[@b40-ndt-13-357]--[@b42-ndt-13-357] Data from recent longer-term studies that incorporate current ADHD trial design concepts also show that there is equivalent efficacy for atomoxetine and methylphenidate, both in adults and children,[@b43-ndt-13-357],[@b44-ndt-13-357] including data from the most recent updated network meta-analysis. Reported effect sizes for atomoxetine in children with ADHD are consistent with those for the stimulants and range from 0.6 to 1.3.[@b45-ndt-13-357] Effect sizes for atomoxetine in adults were estimated to be 0.40 and 0.41, which are within the range reported for methylphenidate in adults as well.[@b45-ndt-13-357]

Because of the high incidence of psychiatric comorbidities in patients with ADHD, an alternative to stimulants that may be contraindicated due to comorbidities could be warranted in some cases. Therefore, understanding the effect of comorbidities on atomoxetine ADHD treatment is clinically relevant. Thus, the aim of this literature review was to provide insight into the effects of comorbid disorders on the efficacy of atomoxetine for the treatment of ADHD symptomology. To the best of our knowledge, there are no comprehensive reviews collectively covering the common ADHD comorbidities in relationship to ADHD treatment for children and adults. The current findings may aid physicians making treatment algorithm decisions that include atomoxetine for patients with ADHD and psychiatric comorbidities.

Methods
=======

The strategy for the literature search was a thorough review conducted in PubMed. Searches were conducted for (atomoxetine \[Title OR Abstract\] AND \[search term (Title OR Abstract)\]). The search was repeated for every item on the list of search terms ([Table 3](#t3-ndt-13-357){ref-type="table"}). The searches were limited to articles in English and covering human clinical data (animal data were not included). Each output item was examined for document type (ie, original article, review, case report), and any article that discussed the efficacy of atomoxetine in the treatment of ADHD in patients who also had 1 of the comorbidities was included in this review. Review articles that were discovered by the search were examined and included in the present review if they contained original research results that were not otherwise captured by the literature search. Moreover, only studies that employed validated ADHD rating scales, such as the Attention-Deficit/Hyperactivity Disorder Rating Scale or the Adult ADHD Self-Report Scale-v1.1, were included. Clinical reports representing results found with a single patient were not included in this review. The searches were not limited by time period. The search terms were selected to cover the common comorbidities, and associated search terms were employed to broaden the search. Further, the general term "anxiety" would return specific disorders such as "social anxiety". [Tables 1](#t1-ndt-13-357){ref-type="table"} and [2](#t2-ndt-13-357){ref-type="table"} indicate the comorbidities that were found to be common based on the literature search and practical clinical experience. [Tables 1](#t1-ndt-13-357){ref-type="table"} and [2](#t2-ndt-13-357){ref-type="table"} also provide published estimates of the incidence of these comorbidities in children and adults with ADHD, respectively. It should be noted that, throughout this review, the terms "child" or "children" are used to describe all patients aged less than 18 years. Although some studies might refer to "adolescents", the age ranges tended to vary, and data were not stratified to select age groups other than those aged less than 18 years and 18 years or more. Unless otherwise indicated, the terms "significant" or "significantly" refer to statistical significance.

Results
=======

The search yielded a total of 50 studies that included ADHD and atomoxetine and at least 1 comorbid disorder. Of these, 37 were in reference to children, whereas 13 were studies performed with adults.

Of the studies performed with children, 23 were double-blind, placebo-controlled randomized clinical trials (RCTs). Among these 23, there were 3 meta-analyses of RCTs and 4 post hoc subgroup analyses of RCTs. One of the RCTs was preceded by an open-label phase, and another contained an open-label extension. In addition, there were 10 open-label studies, including 4 prospective open-label studies. We also found 2 retrospective chart reviews, 1 retrospective review of medical records, and 1 consecutive case series in this search. No results were returned for atomoxetine in ADHD and antisocial personality disorder, binge eating disorders, or obsessive compulsive disorder in children. The studies on atomoxetine use in children with ADHD and at least 1 comorbid disorder identified in our literature search are summarized in [Table 4](#t4-ndt-13-357){ref-type="table"}.

Of the 13 studies that were found with regard to adult patients with ADHD and a comorbidity, 9 were RCTs, including 2 post hoc subgroup analyses. The remaining 4 studies included 3 open-label investigations and a within-subject retrospective design with naturalistic follow-up. No results were found for atomoxetine-treated adults with ADHD and either antisocial personality disorder, binge eating disorders, bipolar disorder, conduct disorders (CDs), oppositional defiant disorder (ODD), learning and language disorders, obsessive compulsive disorder, pervasive developmental disorders/autism spectrum disorder (ASD), sluggish cognitive tempo (SCT), or sleep disorders. The studies on atomoxetine use in adults with ADHD and at least 1 comorbid disorder identified in our literature search are summarized in [Table 5](#t5-ndt-13-357){ref-type="table"}.

Effects of atomoxetine in children with ADHD and comorbidity
------------------------------------------------------------

### Anxiety

Anxiety is one of the common comorbidities found in children with ADHD and affects approximately 18% of children with ADHD, which is substantially greater than the 2% incidence reported in children without ADHD.[@b10-ndt-13-357],[@b93-ndt-13-357] Other studies have estimated the comorbidity of anxiety occurs in 25%--50% of children with ADHD.[@b12-ndt-13-357],[@b13-ndt-13-357] In spite of the rather large incidence of this comorbidity, only 2 studies were found that addressed the use of atomoxetine in young patients with ADHD and anxiety.[@b12-ndt-13-357],[@b46-ndt-13-357] In those studies, atomoxetine improved symptoms of ADHD and did not exacerbate anxiety in these patients. Moreover, there was some evidence that symptoms of anxiety were reduced in these patients.[@b12-ndt-13-357],[@b46-ndt-13-357]

### Bipolar disorder

Comorbid bipolar disorder is also a clinical concern, affecting up to 22% of children with ADHD.[@b16-ndt-13-357] Only 1 open-label study and 1 consecutive case series were found addressing atomoxetine use for ADHD in patients with comorbid bipolar disorder.[@b47-ndt-13-357],[@b48-ndt-13-357] These studies indicated that atomoxetine improved ADHD symptoms, but not bipolar symptoms, in children with these disorders. Atomoxetine use was not associated with any episodes of mania in these studies.[@b47-ndt-13-357],[@b48-ndt-13-357]

### Oppositional defiant disorder

Both ODD and CD rank among the more common of the comorbidities that present with ADHD, which is a significant concern since they are often associated with worsened ADHD symptoms.[@b50-ndt-13-357],[@b94-ndt-13-357] A total of 14 studies were found addressing the use of atomoxetine in this patient population ([Table 4](#t4-ndt-13-357){ref-type="table"}). Overall, atomoxetine produced significant improvements in symptoms of both ADHD and CD/ODD. In addition, a path analysis suggests that atomoxetine may have a specific effect on CD/ODD.[@b51-ndt-13-357] Interestingly, atomoxetine appeared to have a more pronounced effect on hyperactivity in patients with comorbid ODD/CD, and it was suggested that the presence of this disorder may enhance the efficacy of atomoxetine against symptoms of ADHD.[@b58-ndt-13-357] Atomoxetine also protected against relapse in pediatric ADHD patients with concurrent ODD.[@b61-ndt-13-357]

### Depression

Overall, the studies found in this search indicated that atomoxetine was equally effective in reducing symptoms of ADHD in patients with or without comorbid depressive symptoms ([Table 4](#t4-ndt-13-357){ref-type="table"}). In 1 RCT with patients who had ADHD with comorbid major depressive disorder, atomoxetine improved ADHD symptoms but did not improve those of major depressive disorder.[@b63-ndt-13-357] A second RCT showed that atomoxetine given alone or with fluoxetine improved both ADHD and depressive symptoms, but no placebo group was included.[@b46-ndt-13-357] In an open-label study, atomoxetine improved ADHD symptoms, and symptoms of depression were improved in 55% of the patients.[@b14-ndt-13-357] Depressive symptoms were unchanged in 34% and worsened in 11% of patients who had comorbid depression, but significance was not reported.[@b14-ndt-13-357]

### Learning and language disorders

Dyslexia frequently occurs with ADHD, possibly due to common genetic influences and neuropsychological traits.[@b64-ndt-13-357] The search revealed 2 RCTs and 2 open-label studies that examined the effect of atomoxetine in children with ADHD and a language disorder ([Table 4](#t4-ndt-13-357){ref-type="table"}). Overall, atomoxetine was comparable in efficacy against ADHD symptoms in patients with ADHD with or without a learning or language disorder. Importantly, correlation analyses indicated that improvement in ADHD symptoms alone did not explain the improvement in reading scores.[@b67-ndt-13-357]

### Pervasive developmental disorders/ASD

The co-occurrence of pervasive developmental disorders, which include ASDs, with ADHD is estimated to range between 12% and 50%,[@b8-ndt-13-357],[@b20-ndt-13-357] and some studies have estimated that as many as 80% of patients with ADHD have some symptoms of pervasive developmental disorders.[@b19-ndt-13-357] Our search returned 2 blinded, placebo-controlled RCTs, 5 open-label studies, and 1 retrospective examination of patient records addressing atomoxetine and children with ADHD and pervasive developmental disorders or ASD ([Table 4](#t4-ndt-13-357){ref-type="table"}). In general, atomoxetine was significantly superior to placebo in treating symptoms of ADHD in this patient population ([Table 4](#t4-ndt-13-357){ref-type="table"}). It should be noted that the magnitude of the effect of atomoxetine was reduced compared to studies with children with ADHD without ASD.[@b69-ndt-13-357] However, extending the time-course of atomoxetine administration resulted in continued improvement in ADHD symptoms, suggesting that more time is needed for the full effects of atomoxetine to become established in patients with ADHD and ASD.[@b70-ndt-13-357]

### Sluggish cognitive tempo

SCT is an experimental construct rather than a clinical diagnosis that is characterized by drowsiness, daydreaming, lethargy, mental confusion, and slowed thinking/behavior, and it is unclear whether SCT is the inattentive subtype of ADHD or a distinct disorder.[@b95-ndt-13-357] A single double-blind RCT examined the effects of atomoxetine on children with ADHD, dyslexia, or both disorders with regard to SCT symptoms.[@b64-ndt-13-357] Atomoxetine significantly improved SCT symptoms for patients with ADHD alone or ADHD and dyslexia, and also significantly improved the scores of the Parent and Teacher subscales of the Kiddie-Sluggish Cognitive Tempo (K-SCT) for those with dyslexia alone.[@b64-ndt-13-357] While there was a positive correlation (correlation coefficient of 0.40--0.54, *P*\<0.001, for K-SCT Parent subscale score with changes in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Parent-Version:Investigator-Administered and Scored \[ADHDRS-IV-Parent:Inv\] scores; correlation coefficient of 0.33--0.61, *P*≤0.004, for K-SCT Teacher subscale score with changes in Attention-Deficit/Hyperactivity Disorder Rating Scale-IV-Teacher-Version scores; correlation coefficient of 0.16--0.19, *P*≤0.032, for K-SCT Youth subscale score with changes in ADHDRS-IV-Parent:Inv scores) between improvements in ADHD rating scale and in the K-SCT scores, it appears that changes in ADHD symptoms did not fully drive improvements in SCT.[@b64-ndt-13-357]

### Sleep disorders

Children with ADHD have shorter sleep time, longer interrupted sleep time, greater difficulty waking up, and more daytime sleepiness than healthy children.[@b96-ndt-13-357] One RCT ([Table 4](#t4-ndt-13-357){ref-type="table"}) showed that atomoxetine slightly shortened latency to sleep onset and children had less difficulty in falling asleep or waking up and were less irritable.[@b76-ndt-13-357]

### Substance use disorders

Although SUD comorbid with ADHD is a clinical concern even in youths, our search returned only 1 RCT[@b77-ndt-13-357] and 1 open-label prospective study[@b14-ndt-13-357] regarding atomoxetine in this patient population ([Table 4](#t4-ndt-13-357){ref-type="table"}). Atomoxetine, in combination with motivational interviewing/cognitive behavioral therapy (MI/CBT), was not different from placebo and MI/CBT in improving ADHD symptoms or substance use in patients with ADHD and SUD.[@b77-ndt-13-357] The lack of significant difference between the groups was attributed to a large effect from placebo and/or MI/CBT. In the open-label prospective study, only those patients with ADHD and SUD failed to show significant improvement of ADHD symptoms.[@b14-ndt-13-357]

### Tic disorders/Tourette's syndrome

A total of 2 RCTs and 1 prospective, observational open-label study were found to address the activity of atomoxetine on child patients with ADHD and tic disorders, including Tourette syndrome ([Table 4](#t4-ndt-13-357){ref-type="table"}). One RCT showed that atomoxetine was associated with a significant improvement in ADHD symptoms, and some evidence suggests a reduction in tic severity.[@b78-ndt-13-357] A subgroup analysis of patients with comorbid Tourette syndrome from this study showed similar results.[@b79-ndt-13-357] In the open-label study, atomoxetine use was associated with reported improvement in the tic disorder in 65% of the patients, and no change in the remainder (ie, no patients reported a worsening of tic disorder).[@b14-ndt-13-357]

Effects of atomoxetine in adults with ADHD and anxiety
------------------------------------------------------

### Anxiety

We found 4 RCTs, an open-label study, and a post hoc correlation analysis of an RCT when searching for atomoxetine with ADHD and anxiety in adults ([Table 5](#t5-ndt-13-357){ref-type="table"}). Of these 6 reports, 3 RCTs addressed social anxiety disorder (SAD),[@b80-ndt-13-357]--[@b82-ndt-13-357] 1 RCT addressed generalized social anxiety disorder (GSAD),[@b83-ndt-13-357] and 2 addressed generalized anxiety disorder (GAD).[@b84-ndt-13-357] In these reports, atomoxetine improved symptoms of ADHD in individuals with the disorder with or without either of the comorbid anxiety disorders. In addition, atomoxetine reduced symptoms of anxiety in patients with ADHD and with SAD, GSAD, or GAD ([Table 5](#t5-ndt-13-357){ref-type="table"}). Response rates or changes in severity of ADHD symptoms were also significantly greater in patients with ADHD compared to those with ADHD and SAD,[@b80-ndt-13-357] which is consistent with reports that anxiety in general is often associated with a greater severity of ADHD symptoms.[@b97-ndt-13-357] Importantly, atomoxetine produced improvements or no change in anxiety scores of patients with ADHD but with no diagnosis of anxiety disorders.[@b85-ndt-13-357]

### Depression

Although depression with ADHD is a common occurrence,[@b9-ndt-13-357],[@b28-ndt-13-357] we found only 2 RCTs on atomoxetine in adults with ADHD and depression ([Table 5](#t5-ndt-13-357){ref-type="table"}). In both studies, atomoxetine significantly improved ADHD symptoms, but did not produce changes in assessments of depression.[@b85-ndt-13-357],[@b86-ndt-13-357]

### Substance use disorders

The presence of SUD in patients with ADHD is an important clinical concern, occurring up to 4 times the incidence observed in individuals without ADHD.[@b98-ndt-13-357] This search yielded 2 RCTs, a post hoc subgroup analysis of 1 of the RCTs, 2 open-label studies, and a retrospective study with a naturalistic follow-up ([Table 5](#t5-ndt-13-357){ref-type="table"}). Atomoxetine significantly improved ADHD symptoms in individuals with ADHD in each of these studies. However, results with substance abuse were mixed. Atomoxetine significantly reduced cumulative days of heavy drinking, but did not reduce the latency to relapse of heavy drinking.[@b87-ndt-13-357] A subgroup analysis from this study found a significant correlation between improvements in ADHD symptoms and reductions in cravings for alcohol in atomoxetine-treated patients and not in the placebo group, and those that relapsed showed worsening of ADHD symptoms.[@b88-ndt-13-357] In contrast, both atomoxetine and placebo did not change cannabis use in an RCT of patients with ADHD who were also using cannabis.[@b92-ndt-13-357]

An open-label study of adult patients with ADHD and cocaine use showed that atomoxetine significantly improved ADHD symptoms, but did not change cocaine use.[@b91-ndt-13-357] A later open-label study with adult patients with ADHD and polysubstance use (cocaine, cannabis, alcohol, and opioids were the primary abused substances) reported that atomoxetine treatment decreased intensity, frequency, and length of cravings based on the Brief. Substance Craving Scale, each of these dimensions of craving was scored from 0 to 4.[@b90-ndt-13-357]

However, atomoxetine did not reduce the number of times that participants thought that they had a craving within the past 24 hours.[@b90-ndt-13-357] A retrospective study of patients with SUD, with (72%) or without (28%) ADHD, receiving atomoxetine plus treatment-as-usual (TAU) reported a significant reduction in measures of nicotine use when compared to the TAU-alone group.[@b89-ndt-13-357] However, results were presented for the entire group, and not separated by presence or absence of ADHD.[@b89-ndt-13-357]

Discussion
==========

The 50 studies included in this review suggest that atomoxetine is as effective in treating ADHD symptoms in both child and adult patients with ADHD with comorbid psychiatric conditions as those with ADHD without comorbidities. Although ADHD in children has been described for over a century, the same condition in adults has not received serious attention until the 1990s.[@b9-ndt-13-357] It is therefore not surprising that we found 37 studies referencing young patients compared to 13 for adult patients for this review.

Anxiety, depression, mania, and tics have been reported as adverse events in patients taking atomoxetine.[@b37-ndt-13-357],[@b38-ndt-13-357] However, the atomoxetine product label also states that clinical trials have reported that atomoxetine improves symptoms of ADHD in patients with comorbid anxiety and tic disorders, without worsening these comorbid symptoms.[@b37-ndt-13-357],[@b38-ndt-13-357] In the studies reviewed, atomoxetine improved various ADHD symptoms in cohorts with and without comorbidities. This observation is supported by a recent systematic review of 24 studies (RCTs and within-subject designs) that concluded that the presence of a comorbidity did not lessen the efficacy of atomoxetine in treating ADHD symptoms.[@b99-ndt-13-357] Importantly, this systematic review did not make clear that in both adults and children, the efficacy of atomoxetine is similar to stimulants and hence atomoxetine has an important role in ADHD treatment for many patients with and without comorbid disorders.[@b43-ndt-13-357],[@b44-ndt-13-357]

In the studies reviewed, there is no evidence of worsening of any of the comorbidities examined, and in some cases, there is significant improvement. It is important however to differentiate usage of atomoxetine when a comorbidity is present from usage in that comorbid condition alone. Atomoxetine does not improve symptoms of anxiety in patients with anxiety disorders but without ADHD. For example, a placebo-controlled RCT showed that atomoxetine was no different from placebo in improving anxiety scores in patients with GSAD.[@b83-ndt-13-357] A post hoc correlation analysis of an RCT of ADHD patients with SAD who were treated with atomoxetine revealed that improvements in anxiety were directly correlated with improvements in symptoms of ADHD.[@b100-ndt-13-357] Moreover, atomoxetine did not exacerbate comorbid anxiety.[@b100-ndt-13-357] It is therefore likely that when improvements in anxiety symptoms are seen, it is probably related to improvement of ADHD symptoms.

Depression is an important clinical concern in patients with ADHD, as it occurs at a 5-fold greater incidence in these patients than in the population at large.[@b101-ndt-13-357] A link between depression and ADHD is suggested by imaging studies that show that these 2 disorders share common brain regions and neural pathways.[@b102-ndt-13-357] In comorbid patients treated with atomoxetine, it is likely that reported improvements in depressive symptoms result from an improvement in ADHD, and not from a direct antidepressant effect of atomoxetine. This interpretation is consistent with the RCTs that showed that atomoxetine does not act as an antidepressant.[@b103-ndt-13-357]--[@b106-ndt-13-357] The studies in which depression was comorbid with ADHD showed that the presence of depressive symptoms did not adversely impact the efficacy of atomoxetine against ADHD.

Although tics are listed as a possible adverse event with atomoxetine, several treatment guidelines indicate that atomoxetine is preferred over the stimulants for patients with ADHD and comorbid tic disorders. The European ADHD Guidelines Group concluded that the stimulants could worsen comorbid tics, whereas atomoxetine significantly improves them.[@b107-ndt-13-357] The National Institute for Health and Care Excellence (NICE) suggests atomoxetine or methylphenidate when tic disorders or Tourette syndrome is present.[@b108-ndt-13-357]

Both child and adult patients with ADHD are at a higher risk of SUD.[@b29-ndt-13-357],[@b109-ndt-13-357],[@b110-ndt-13-357] There is an approximately 4-fold greater incidence of SUD in adult ADHD patients compared to individuals without ADHD.[@b98-ndt-13-357] Despite variable evidence for the role of stimulants in the management of SUD among patients with ADHD, there exists a clinical concern regarding the use of the psychostimulants in patients with SUD, since these drugs show some abuse liability.[@b98-ndt-13-357],[@b110-ndt-13-357] In contrast, atomoxetine has no abuse liability,[@b111-ndt-13-357] and thus often will be a first-choice treatment in patients with concern for SUD.[@b111-ndt-13-357] Treatment guidelines suggest the use of atomoxetine or of extended-release formulations of methylphenidate in this population to reduce abuse liability.[@b107-ndt-13-357],[@b112-ndt-13-357],[@b113-ndt-13-357]

Although atomoxetine may be preferable over other treatments for ADHD in the presence of certain psychiatric comorbidities described, there remains reluctance among some clinicians to administer atomoxetine first because of perceptions that it may be less effective. However, a recent systematic review and a network meta-analysis have shown similar efficacy for responders.[@b43-ndt-13-357],[@b44-ndt-13-357] Many RCTs specifically exclude patients with specific comorbid disorders such as major depressive disorder and anxiety. Our search found clinical studies addressing only 3 comorbid disorders in adults: anxiety, depression, and SUD. There are more studies performed with children, but no data were found with regard to antisocial personality disorder, binge eating disorders, or obsessive compulsive disorder. While it is known that adults with ADHD have irregular sleep--wake cycles and disrupted sleep patterns, we found no studies addressing the effect of atomoxetine on sleep in adults with ADHD, and only 1 study on children with ADHD. Overall, although there is an association of binge eating disorder with ADHD,[@b114-ndt-13-357] there is currently a dearth of evidence as to its incidence, and little guidance on appropriate therapy. There is an appreciable level of comorbidity of bipolar disorder with ADHD. Estimates of comorbid bipolar disorder range up to 22% of children with ADHD,[@b16-ndt-13-357] and as high as 47% in adults.[@b27-ndt-13-357] In spite of these estimates, there are few studies on the treatment of individuals with ADHD and bipolar disorder.[@b115-ndt-13-357] Care should be taken in treating ADHD patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode.[@b37-ndt-13-357] This cumulative review and analysis of studies of atomoxetine in patients with common comorbidities should help improve current treatment guidelines for ADHD.

Limitations
-----------

An important limitation of this review is that the activity of atomoxetine in ADHD with some comorbid disorders is not well examined. Whereas some of these conditions are subjected to rigorous placebo-controlled, double-blind RCTs, some, such as ODD, are lacking in such studies because individuals with these comorbidities are often excluded from ADHD clinical trials. Also, there are only a few head-to-head comparisons of atomoxetine vs methylphenidate or the other psychostimulants in ADHD patients with common comorbidities. A limitation of this analysis is that it is not a systematic review.

Summary and conclusion
======================

Overall, atomoxetine shows good efficacy in improving symptoms of ADHD in children and adults. Based on the studies reported in the present review, the presence of comorbid psychiatric disorders does not appear to alter the efficacy of atomoxetine in treating ADHD. Moreover, atomoxetine may be preferable to psychostimulants in the treatment of ADHD in the presence of psychiatric disorders contraindicated for stimulants, while providing similar levels of efficacy and tolerability.
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###### 

Incidence of comorbidities with ADHD in children

  Comorbidity                             Incidence                         References
  --------------------------------------- --------------------------------- ----------------------------------------
  Anxiety                                 18%                               Larson et al[@b10-ndt-13-357]
                                          25%--35%                          Geller et al[@b12-ndt-13-357]
                                          25%--50%                          Sciberras et al[@b13-ndt-13-357]
                                          27%                               Bakken et al[@b14-ndt-13-357]
  Binge eating                            12%                               Reinblatt et al[@b15-ndt-13-357]
  Bipolar disorder                        0%--20%                           Taurines et al[@b16-ndt-13-357]
                                          7%--22%                           Singh et al[@b17-ndt-13-357]
                                          5%                                Bakken et al[@b14-ndt-13-357]
  Conduct disorder/ODD                    30%--50%                          Dopheide and Pliszka[@b3-ndt-13-357]
                                          40%--60%                          Biederman et al[@b18-ndt-13-357]
                                          24%                               Bakken et al[@b14-ndt-13-357]
  Depression                              21%                               Bakken et al[@b14-ndt-13-357]
                                          16%--26%                          Gillberg et al[@b19-ndt-13-357]
  Learning and language disorders         23%                               Bakken et al[@b14-ndt-13-357]
  46%                                     Larson et al[@b10-ndt-13-357]     
  Obsessive compulsive disorder           2%                                Jensen and Steinhausen[@b8-ndt-13-357]
  Pervasive developmental disorders/ASD   12%                               Jensen and Steinhausen[@b8-ndt-13-357]
                                          30%--50%                          Reichow et al[@b20-ndt-13-357]
  Substance abuse disorders               22%                               Kollins[@b21-ndt-13-357]
  Tic disorders/Tourette's syndrome       7%                                Bakken et al[@b14-ndt-13-357]
  20%--30%                                Taurines et al[@b16-ndt-13-357]   

**Note:** No data were found in the literature for ADHD and antisocial personality disorder in children (ie, \<18 years of age).

**Abbreviations:** ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum disorder; ODD, oppositional defiant disorder.

###### 

Incidence of comorbidities with ADHD in adults

  Comorbidity               Incidence   Reference
  ------------------------- ----------- ---------------------------------------
  Anxiety                   25%--35%    Kessler et al[@b9-ndt-13-357]
  Bipolar disorder          5%--20%     Perugi and Vannucchi[@b26-ndt-13-357]
                            47%         Wingo and Ghaemi[@b27-ndt-13-357]
                            19%         Kessler et al[@b9-ndt-13-357]
  Depression                19%         Kessler et al[@b9-ndt-13-357]
                            30%--50%    Kolar et al[@b28-ndt-13-357]
  Substance use disorders   47%         Kollins[@b21-ndt-13-357]
                            30%         Biederman[@b29-ndt-13-357]

**Note:** No data were found in the literature for the following comorbidities in adults (ie, ≥18 years of age): antisocial personality disorder, binge eating, conduct disorder/ODD, learning and language disorders, obsessive compulsive disorder, pervasive developmental disorders/ASD, and tic disorders/Tourette syndrome.

**Abbreviations:** ADHD, attention-deficit hyperactivity disorder; ASD, autism spectrum disorder; ODD, oppositional defiant disorder.

###### 

Comorbidities and associated terms used in PubMed literature search

  ---------------------------------------------------- --------------------------------
  Antisocial personality disorder                      Pervasive development disorder
   Antisocial                                          Asperger
   Personality                                         Autism
  Anxiety                                              Autistic
   Anxiety                                             Pervasive
  Binge eating disorder                                PDD
   Binge                                               Rett
  Bipolar disorder                                     Sleep disorder
   Bipolar                                             Hypersomnia
   Mania                                               Insomnia
  Conduct disorder or oppositional defiance disorder   Sleep
   Conduct                                             Sluggish cognitive tempo
   Oppositional                                        Sluggish
   Defiance                                            Tempo
   ODD                                                 SCT
  Depression                                           Substance abuse disorder
   Depression                                          Abuse
  Learning disorder or language disorder               Dependence
   Language                                            Substance
   Learning                                            SUD
   Dyslexia                                            Alcohol
   Reading                                             Tic disorder
  Obsessive compulsive disorder                        Tic
   Obsessive                                           Tourette
   Compulsive                                          
   OCD                                                 
  ---------------------------------------------------- --------------------------------

**Notes:** The search performed was for "atomoxetine" AND the "comorbidity term"; eg, (atomoxetine\[Title/Abstract\]) AND bipolar\[Title/Abstract\].

**Abbreviations:** OCD, obsessive compulsive disorder; ODD, oppositional defiant disorder; PDD, pervasive developmental disorder; SCT, sluggish cognitive tempo; SUD, substance use disorder.

###### 

Search results for ADHD and comorbidities in children

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                                                      Type of study                                          Age range                             Main findings
  ------------------------------------------------------------------------------- ------------------------------------------------------ ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Antisocial personality disorder**                                                                                                                                          

  --                                                                              --                                                     --                                    --

  **Anxiety**                                                                                                                                                                  

  Kratochvil et al[@b46-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}   RCT                                                    7--17 years                           ATX plus PBO not significantly different from ATX and fluoxetine. Significant improvements in ADHD symptoms (ADHD-RS) and anxiety symptoms (MASC)

  Geller et al[@b12-ndt-13-357]                                                   RCT                                                    8--17 years                           ATX significantly improved ADHD symptoms (ADHD-RS) and anxiety (PARS)[\*](#tfn9-ndt-13-357){ref-type="table-fn"}\
                                                                                                                                                                               ATX did not exacerbate comorbid anxiety

  **Binge eating disorders**                                                                                                                                                   

  --                                                                              --                                                     --                                    --

  **Bipolar disorder**                                                                                                                                                         

  Chang et al[@b47-ndt-13-357]                                                    Open-label                                             6--17 years                           ATX improved ADHD symptoms\
                                                                                                                                                                               ATX did not change symptoms of depression (CDRS) or of mania (YMRS) in Pts with ADHD and bipolar disorder

  Hah and Chang[@b48-ndt-13-357]                                                  Consecutive case series                                                                      Pts with ADHD and bipolar disorder treated with ATX and mood stabilizers\
                                                                                                                                                                               Six of 7 Pts showed significant improvement in ADHD symptomsNo Pts had episodes of hypomania or mania

  **Conduct disorders and oppositional defiant disorder**                                                                                                                      

  Newcorn et al[@b49-ndt-13-357]                                                  RCT                                                    8--18 years                           ATX produced clinically meaningful improvements in ADHD (ADHD-RS) and ODD (CPRS-R:S) symptoms\
                                                                                                                                                                               Pts with ADHD plus ODD required more ATX than ADHD alone\
                                                                                                                                                                               Pts with ADHD plus ODD remained more severely affected

  Bangs et al[@b50-ndt-13-357]                                                    RCT                                                    6--12 years                           ATX superior to PBO for ODD at 2 and 5, but not 8 weeks (SNAP-IV ODD)\
                                                                                                                                                                               ATX superior to PBO for ADHD (SNAP-IV ADHD ratings; CGI scales for severity, improvement, and for the parent version) at 8 weeks

  Biederman et al[@b18-ndt-13-357]                                                Meta-analysis of 3 RCTs                                6--16 years                           ATX improved ADHD symptoms in Pts with and without ODD (ADHD-RS; CGI-ADHD-S)\
                                                                                                                                                                               ATX improved ODD (CPRS-R:S oppositional scores), and ODD improvement correlated with ADHD improvement

  Dittmann et al[@b51-ndt-13-357]                                                 RCT                                                    6--17 years                           ATX was superior to PBO for ADHD and CD/ODD symptoms (SNAP-IV ADHD and ODD subscales)\
                                                                                                                                                                               Path analysis suggests ATX has a specific effect on CD/ODD

  Dell'Agnello et al[@b52-ndt-13-357]                                             RCT                                                    6--15 years                           ATX was significantly superior to PBO in improving ADHD (SNAP-IV ADHD subscale; CGI-ADHD-S) and ODD (SNAP-IV ODD subscale) symptoms

  Garg et al[@b53-ndt-13-357]                                                     RCT                                                    6--14 years                           ATX and methylphenidate improved ADHD and ODD symptoms (VADPRS) in Pts with ADHD and comorbid ODD

  Cheng et al[@b54-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}        Meta-analysis of 7 RCTs                                Not stated                            ATX superior to PBO in reducing ADHD (ADHD-RS-IV; CGI-S; CTRS-R:S) and ODD symptoms (Oppositional Index of CTRS-R:S)\
                                                                                                                                                                               ATX produced smaller changes in ADHD symptoms in Pts with ADHD and ODD; ATX improved quality of life (CHQ)

  Wehmeier et al[@b55-ndt-13-357]                                                 Post hoc subgroup analyses of RCT                      6--17 years                           ATX improved quality of life and self-esteem, in Pts with ADHD and ODD (KINDL-R)

  Waxmonsky et al[@b56-ndt-13-357]                                                Open-label                                             6--12 years                           Switching to bid ATX with a slight increase in dose improved ODD, but not ADHD, symptoms (IOWA Connors Rating Scale) in children with both disorders

  van Wyk et al[@b57-ndt-13-357]                                                  Meta-analysis of 7 RCTs                                6--16 years                           ATX and methylphenidate produced similar results in Pts with ADHD and either with or without ODD

  Wehmeier et al[@b58-ndt-13-357]                                                 Post hoc subgroup analyses of RCT                      6--12 years                           ATX reduced severity of ADHD symptoms in Pts with or without ODD/CD (cb-CPT/MT); ATX had more pronounced effect on hyperactivity in Pts with comorbid ODD/CD

  Ercan et al[@b59-ndt-13-357]                                                    Retrospective chart review                             Mean: 9.97±1.87 years                 ATX improved symptoms of ADHD, but not ODD, in Pts with both (CGI)

  Kaplan et al[@b60-ndt-13-357]                                                   Post hoc subgroup analyses of RCT                      7--13 years                           ATX improved ADHD scores (ADHD-RS-IV; CGI-ADHD-S; CPRS-R:S) but not ODD scores (CPRS-R:S Oppositional subscore) in Pts with both ADHD and ODD

  Hazell et al[@b61-ndt-13-357]                                                   Open-label                                             6--15 years                           ODD did not change relapse rate or latency in Pts with ADHD after ATX treatment end

  **Depression**                                                                                                                                                               

  Cheng et al[@b54-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}        Meta-analyses of 7 RCTs                                Not stated                            ATX superior to PBO in reducing ADHD (ADHD-RS-IV; CGI-S; CTRS-R:S)\
                                                                                                                                                                               NNTs were similar for ATX in Pts with and without comorbid depression

  Scott et al[@b62-ndt-13-357]                                                    Retrospective chart review                             5--17 years                           No significant differences in treatment success or treatment failure with ATX with ADHD and comorbid depression

  Bangs et al[@b63-ndt-13-357]                                                    RCT                                                    12--18 years                          ATX superior to PBO in improving ADHD symptoms (ADHD-RS) ATX not different from PBO for symptoms of depression (CDRS-R) in Pts with ADHD comorbid MDD

  Kratochvil et al[@b46-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}   RCT                                                    7--17 years                           Marked improvement in ADHD symptoms (ADHD-RS) and depression symptoms (CDRS-R)\
                                                                                                                                                                               No difference between ATX + PBO and ATX + fluoxetine

  Bakken et al[@b14-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}       Prospective, observational, longitudinal, open-label   6--17 years                           ATX improved ADHD symptoms (PGI-ADHD-S) in Pts with ADHD with or without depression\
                                                                                                                                                                               Depressive symptoms improved in 55% of these Pts

  **Learning and language disorders**                                                                                                                                          

  Wietecha et al[@b64-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}     RCT with open-label extension                          10--16 years                          ATX significantly better than PBO in improving ADHD symptoms (ADHD-RS) in Pts with ADHD and ADHD with comorbid dyslexia\
                                                                                                                                                                               No difference between groups for ADHD symptoms\
                                                                                                                                                                               ATX improved Phonological Loop and Central Executive components of WMTB-C

  de Jong et al[@b65-ndt-13-357]                                                  RCT                                                    8--12 years                           ATX was similarly effective against ADHD symptoms (ADHD-RS) in Pts with ADHD alone or ADHD and RD\
                                                                                                                                                                               ATX improved visuospatial working memory (CBTT) and inhibition (SSRT) in Pts with ADHD and RD, but not with ADHD or RD alone\
                                                                                                                                                                               Note age and IQ differences among groups

  Sumner et al[@b66-ndt-13-357]                                                   Open-label                                             10--16 years                          ATX improved ADHD symptoms (ADHD-RS) and reading scores (K-TEA) in Pts with ADHD and with or without comorbid dyslexia\
                                                                                                                                                                               Change in WMTB-C central executive score was significantly greater for the ADHD group\
                                                                                                                                                                               Change in WMTB-C phonological loop score was significantly greater in the ADHD plus dyslexia group

  Shaywitz et al[@b67-ndt-13-357]                                                 Open-label, parallel design                            10--16 years                          ATX produced significant improvements in ADHD symptoms (ADHD-RS) in Pts with ADHD and those with ADHD and dyslexia\
                                                                                                                                                                               Both groups showed improved reading scores (K-TEA)\
                                                                                                                                                                               Weak correlation between improved ADHD and reading scores

  **Obsessive compulsive disorder**                                                                                                                                            

  --                                                                              --                                                     --                                    --

  **Pervasive developmental disorders/autism spectrum disorder**                                                                                                               

  Arnold et al[@b68-ndt-13-357]                                                   RCT                                                    5--15 years (mental age ≥18 months)   ATX significantly superior to PBO against hyperactive symptoms of ADHD (ABC-H; CGI =1 or 2) in Pts with ADHD and ASD ATX superior (not significant) to PBO against inattentive symptoms of ADHD

  Harfterkamp et al[@b69-ndt-13-357]                                              RCT                                                    6--17 years                           ATX superior to PBO for symptoms of ADHD (ADHD-RS) in Pts with ADHD and ASD

  Harfterkamp et al[@b70-ndt-13-357]                                              Open-label extension                                   6--17 years                           Continued ATX provided continuation of improvement in ADHD symptoms in Pts with ADHD and ASD

  Troost et al[@b71-ndt-13-357]                                                   Open-label prospective study                           6--14 years                           ATX improved ADHD symptoms in PDD Pts with ADHD symptoms (ADHD-RS; CPRS-R:S)\
                                                                                                                                                                               ATX improved hyperactivity symptoms in ABC scale

  Fernández-Jaén et al[@b72-ndt-13-357]                                           Open-label prospective study                           Mean: 8.7±3.38 years                  ATX improved ADHD symptoms in ADHD Pts with PDD symptoms (ADHD-RS; CPRS-R:S; CGI)

  Jou et al[@b73-ndt-13-357]                                                      Retrospective review of medical records                6--19 years                           Pts with PDD showed improvement with ATX in conduct, hyperactivity, inattention, and learning (CGI)

  Posey et al[@b74-ndt-13-357]                                                    Open-label prospective study                           6--14 years                           Seventy-five percent of ADHD/PDD Pts receiving ATX "much improved" or "very much improved" on CGI\
                                                                                                                                                                               ATX significantly improved ADHD symptoms on SNAP-IV and ABC-H

  Charnsil[@b75-ndt-13-357]                                                       Open-label study                                       7--15 years                           Pts with severe ASD and symptoms of ADHD showed no significant improvement with ATX in hyperactive ADHD symptoms (ABC-H) ATX improved CGI scores

  **Sluggish cognitive tempo**                                                                                                                                                 

  Wietecha et al[@b64-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}     RCT                                                    10--16 years                          ATX improved K-SCT scores in Pts with ADHD alone or ADHD and dyslexia Positive correlation between improvements in ADHD-RS and in the K-SCT scores: K-SCT Parent subscale score vs ADHDRS-IV-Parent:Inv scores: correlation coefficient: 0.40--0.54, *P*\<0.001\
                                                                                                                                                                               K-SCT Teacher subscale score vs ADHDRS-IV-Teacher-Version scores: correlation coefficient: 0.33--0.61, *P*\<0.004\
                                                                                                                                                                               K-SCT Youth subscale score vs ADHDRS-Parent:Inv scores: correlation coefficient: 0.16--0.19, *P*≤0.032

  **Sleep disorders**                                                                                                                                                          

  Sangal et al[@b76-ndt-13-357]                                                   Cross-over RCT                                         10.1±2.0 years                        ATX improved ADHD symptoms (ADHD-RS)\
                                                                                                                                                                               ATX showed significantly shorter latency to sleep vs methylphenidate\
                                                                                                                                                                               ATX was associated with less difficulty in falling asleep, waking up, and less irritability (parent and children reports) vs methylphenidate

  **Substance use disorders**                                                                                                                                                  

  Thurstone et al[@b77-ndt-13-357]                                                Single-site RCT                                        13--19 years                          ATX and PBO improved ADHD symptoms (DSM-IV ADHD symptom checklist)\
                                                                                                                                                                               No difference in ADHD symptoms (DSM-IV ADHD symptom checklist) or nonnicotine substance use in ATX + MI/CBT vs PBO + MI/CBT groups

  Bakken et al[@b14-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}       Open-label prospective study                           6--17 years                           ATX reduced symptoms of ADHD (PGI-ADHD-S) in Pts with ADHD\
                                                                                                                                                                               No significant improvement in Pts with ADHD and SUD

  **Tic disorders/Tourette syndrome**                                                                                                                                          

  Allen et al[@b78-ndt-13-357]                                                    RCT                                                    7--17 years                           ATX significantly reduced ADHD symptoms (ADHD-RS) and tic severity (CGI-Tic/Neuro-S)\
                                                                                                                                                                               ATX markedly reduced tics (YGTSS; Tic Symptom Self-Report) in Pts with ADHD and tic disorders

  Spencer et al[@b79-ndt-13-357]                                                  Post hoc subgroup analyses of RCT                      7--17 years                           ATX significantly superior to PBO against ADHD symptoms (ADHD-RS)\
                                                                                                                                                                               ATX significantly superior to PBO in reducing tic severity (YGTSS; CGI-Tic/Neuro-S) in Pts with ADHD and Tourette syndrome

  Bakken et al[@b14-ndt-13-357],[\#](#tfn8-ndt-13-357){ref-type="table-fn"}       Prospective, observational, open-label study           6--17 years                           ATX significantly improved ADHD symptoms (PGI-ADHD-S)\
                                                                                                                                                                               Improved tic disorder in 65%, no change in 35% ATX did not worsen tics in Pts with ADHD and tic disorders
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Dashes indicate that no literature results were found on search.

The source included more than 1 comorbidity, and appears more than once in the table. Thus, there are 37 articles, 4 of which appear 2 or more times.

A post hoc correlation analysis of this RCT revealed that improvements in anxiety were directly correlated with improvements in symptoms of ADHD.[@b100-ndt-13-357]

**Abbreviations:** ABC, Aberrant Behavior Checklist; ABC-H, Aberrant Behavior Checklist-Hyperactivity Scale; ADHD, attention-deficit hyperactivity disorder; ADHD-RS-IV, Attention-Deficit/Hyperactivity Disorder Rating Scale-IV; ADHDRS-IV-Parent:Inv, ADHD Rating Scale-IV-Parent-Version:Investigator-Administered and Scored; ADHDRS-IV-Teacher-Version, ADHD Rating Scale-IV-Teacher-Version; ADHD-RS, Attention-Deficit/Hyperactivity Disorder Rating Scale; ASD, autism spectrum disorder; ATX, atomoxetine; cb-CPT, computer-based continuous performance test; CBTT, Corsi Block Tapping Test; CD, conduct disorder; CDRS, Children's Depression Rating Scale; CDRS-R, Children's Depression Rating Scale-Revised; CGI, Clinical Global Impression; CGI-ADHD-S, Clinical Global Impression-Attention-Deficit Hyperactivity Disorder-Severity; CGI-S, Clinical Global Impression-Severity; CGI-Tic/Neuro-S, CGI Tic/Neurologic Severity Scale; CHQ, Child Health Questionnaire; CPRS-R:S, Conners' Parent Rating Scale-Revised Short Form; CTRS-R:S, Conners' Teacher Rating Scale-Revised Short Form; DSM-IV, *Diagnostic and Statistical Manual of Mental Disorders*, 4th Edition; IQ, intelligence quotient; KINDL-R, Revidierter KINDer Lebensqualitätsfragebogen; K-SCT, Kiddie-Sluggish Cognitive Tempo; K-TEA, Kaufman Test of Educational Achievement; MASC, Multidimensional Anxiety Scale for Children; MDD, major depressive disorder; MI/CBT, motivational interviewing/cognitive behavioral therapy; MT, infrared motion tracking device; NNTs, numbers needed to treat; ODD, oppositional defiant disorder; PARS, Pediatric Anxiety Rating Scale; PBO, placebo; PDD, pervasive developmental disorder; PGI-ADHD-S, Physician Global Impression: ADHD Severity; Pts, patients; RCT, randomized clinical trial; RD, reading disorder; SNAP-IV, Swanson, Nolan, and Pelham Rating Scale-Revised; SSRT, Stop Signal Reaction Time; SUD, substance use disorder; VADPRS, Vanderbilt ADHD Diagnostic Parent Rating scale; WMTB-C, Working Memory Test Battery for Children; YGTSS, Yale Global Tic Severity Scale; YMRS, Young Mania Rating Scale.

###### 

Search results for ADHD and comorbidities in adults

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  References                                                                   Type of study                                                     Age range         Main findings
  ---------------------------------------------------------------------------- ----------------------------------------------------------------- ----------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Antisocial personality disorder**                                                                                                                              

  --                                                                           --                                                                --                --

  **Anxiety**                                                                                                                                                      

  Social anxiety disorder                                                                                                                                          

   Adler et al[@b80-ndt-13-357]                                                Multicenter RCT                                                                     ATX significantly better than PBO\
                                                                                                                                                                   Response rate better in ADHD (51%) than ADHD plus SAD (42%)\
                                                                                                                                                                   CAARS:Inv:SV score improvement better in ADHD than ADHD + SAD

   Adler et al[@b81-ndt-13-357]                                                Multicenter RCT                                                                     ATX significantly improved ADHD symptoms (CAARS:Inv:SV) and anxiety scores (LSAS; CGI-OS; STAI), and quality of life (AAQoL) compared to PBO in Pts with ADHD and SAD. SAS was markedly improved

   Donnelly et al[@b82-ndt-13-357]                                             Post hoc subgroup analyses of RCT                                                   ATX-mediated improvements in ADHD directly correlated with anxiety improvement in Pts with ADHD and SAD

   Ravindran et al[@b83-ndt-13-357]                                            RCT                                                               18--65 years      ATX not different from PBO in Pts with GSAD and without ADHD (LSAS)

  Generalized anxiety disorder                                                                                                                                     

   Gabriel and Violato[@b84-ndt-13-357]                                        Open label                                                        18--65 years      ATX as adjunctive to SSRIs or to SNRIs improved symptoms of ADHD (ASRS-v1.1; CGI-S) and anxiety (HAM-A) in Pts with ADHD and GAD

   Young et al[@b85-ndt-13-357],[\#](#tfn12-ndt-13-357){ref-type="table-fn"}   RCT                                                               ≥18 years         ATX improved ADHD scores, no change in anxiety (STAI) in Pts with ADHD and without anxiety

  **Binge eating disorders**                                                                                                                                       

  --                                                                           --                                                                --                --

  **Bipolar disorder**                                                                                                                                             

  --                                                                           --                                                                --                --

  **Conduct disorders and oppositional defiant disorder**                                                                                                          

  --                                                                           --                                                                --                --

  **Depression**                                                                                                                                                   

  Young et al[@b85-ndt-13-357],[\#](#tfn12-ndt-13-357){ref-type="table-fn"}    RCT                                                               ≥18 years         ATX was significantly better than PBO in improving ADHD symptoms (CAARS-Inv:SV), but had no change on depressive symptoms (MADRS)

  Durell et al[@b86-ndt-13-357]                                                RCT                                                               18--30 years      ATX improved ADHD symptoms (CAARS-Inv:SV), but had no change on depressive symptoms (MADRS)

  **Learning and language disorders**                                                                                                                              

  --                                                                           --                                                                --                --

  **Obsessive compulsive disorder**                                                                                                                                

  --                                                                           --                                                                --                --

  **Pervasive developmental disorders/autism spectrum disorder**                                                                                                   

  --                                                                           --                                                                --                --

  **Sluggish cognitive tempo**                                                                                                                                     

  --                                                                           --                                                                --                --

  **Sleep disorders**                                                                                                                                              

  --                                                                           --                                                                --                --

  **Substance use disorders**                                                                                                                                      

  Wilens et al[@b87-ndt-13-357]                                                RCT                                                               ≥18 years         ATX significantly superior to PBO in reducing ADHD symptoms (AISRS)\
                                                                                                                                                                   ATX reduced cumulative days of heavy drinking\
                                                                                                                                                                   ATX did not reduce latency to relapse of heavy drinking

  Wilens et al[@b88-ndt-13-357]                                                Post hoc subgroup analyses of RCT                                 ≥18 years         Significant correlation between improvements in ADHD symptoms and reductions in craving for alcohol in ATX, and not PBO, group PBO, but not ATX, group with relapse to alcohol had significant worsening of ADHD symptoms

  Benegal et al[@b89-ndt-13-357]                                               Within-subject retrospective design with naturalistic follow-up   27.2±5.9 years    Pts with (72%) and without DSM-IV ADHD diagnosis\
                                                                                                                                                                   ATX + TAU significantly improved ASRS-v1.1 scores, reduced turnaround time, increased abstinence periods, improved quality of life, and reduced cigarette smoking vs TAU

  Adler et al[@b90-ndt-13-357]                                                 Open-label                                                        36.8±10.0 years   ATX improved ADHD symptoms (AISRS) and significantly reduced intensity, frequency, and length of cravings (BSCS) in Pts with ADHD and SUD

  Levin et al[@b91-ndt-13-357]                                                 Open-label                                                        39.3±6.6 years    ATX improved ADHD symptoms (AARS-v1.1) but did not reduce cocaine use in Pts with ADHD and cocaine dependency

  McRae-Clark et al[@b92-ndt-13-357]                                           RCT                                                               18--65 years      ATX significantly superior to PBO in treating ADHD symptoms (CGI-I)

                                                                                                                                                                   ATX and PBO did not reduce cannabis use in Pts with ADHD and cannabis dependency
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:**

Young et al[@b85-ndt-13-357] appears twice, as it addresses more than 1 comorbidity. Dashes indicate that no literature results were found on search.

**Abbreviations:** AAQoL, Adult ADHD Quality of Life Scale-29; AARS, Adult ADHD Rating Scale; ADHD, attention-deficit hyperactivity disorder; AISRS, ADHD Investigator Symptom Rating Scale; ASRS-v1.1, Adult ADHD Self-Report Scale-v1.1; ATX, atomoxetine; BSCS, Brief Substance Craving Scale; CAARS:Inv:SV, Conners' Adult ADHD Rating Scale:Investigator-Rated:Screening Version; CGI-I, Clinical Global Impression-Global Improvement; CGI-OS, Clinical Global Impression-Overall Severity; CGI-S, Clinical Global Impression-Severity; DSM-IV, *Diagnostic and Statistical Manual of Mental Disorders*, 4th Edition; GAD, generalized anxiety disorder; GSAD, generalized social anxiety disorder; HAM-A, Hamilton Anxiety Scale; LSAS, Liebowitz Social Anxiety Scale; MADRS, Montgomery--Åsberg Depression Rating Scale; PBO, placebo; Pts, patients; RCT, randomized controlled trial; SAD, social anxiety disorder; SAS, Social Adjustment Scale; SNRI, selective noradrenergic reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; STAI, State-Trait Anxiety Inventory; SUD, substance use disorder; TAU, treatment-as-usual.
